

**FAX**

**Tender Results**

Level 9, Cigna House,  
40 Mercer Street, PO Box 10-254,  
Wellington 6143, New Zealand

Phone 64-4-460-4990

Fax 64-4-460-4995

[www.pharmac.govt.nz](http://www.pharmac.govt.nz)

**To:** All Suppliers and Wholesalers

**From:** Yvonne Chen

**Date:** 30 September 2008

**No of Pages (including this one):** 4

Dear Supplier/Wholesaler

**TENDER RESULTS**

The PHARMAC Board (or Chief Executive under delegated authority) has resolved to accept tenders for Sole Subsidised Supply and Hospital Supply Status for some of the products listed in the Invitation to Tender dated 21 December 2007 and the Invitation to Tender dated 15 December 2006.

Some of the pharmaceuticals that will be delisted when the period of sole supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts until such time as the pharmaceuticals are delisted and PHARMAC will continue to subsidise their pharmaceuticals accordingly.

**Product Notification Forms**

Please note that for all changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H) suppliers are required to notify PHARMAC and the Guild by 4pm **10<sup>th</sup> October 2008**. More information and product notification forms can be downloaded from our website – [www.pharmac.govt.nz/schedule.asp](http://www.pharmac.govt.nz/schedule.asp).

**2007/08 Tender**

**Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule**

1. Tenders awarded to listed pharmaceuticals where no other brand is listed – subsidy changes on **1 November 2008** and Sole Subsidised Supply commences on **1 February 2009**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current Subsidy	New tender subsidy	Sole supply brand (Supplier)
Promethazine Hydrochloride	Tab 10 mg; 50 tablets, blister	\$2.75	\$2.72	Allersoothe (AFT)
Promethazine Hydrochloride	Tab 25 mg; 50 tablets, blister	\$4.50	\$4.44	Allersoothe (AFT)
Prednisone*	Tab 20 mg; 500 tablets, bottle	\$30.56	\$29.03	Apo-Prednisone (Apotex)
Zopiclone	Tab 7.5 mg; 500 tablets, bottle	\$22.13	\$21.02	Apo-Zopiclone (Apotex)

\*Sole Subsidised Supply for prednisone 20 mg tablets will commence on 1 January 2009, to be consistent with the other strengths of prednisone.

2. Tenders awarded to pharmaceuticals where at least one other brand is listed – subsidy changes for tender winning brand at the tender subsidy will occur on **1 November 2008**, reference pricing of non-tender winning brand will occur on **1 January 2009** and Sole Subsidised Supply commences on **1 April 2009**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current subsidy	New tender subsidy	Sole supply brand (Supplier)	Brands affected by reference pricing and delisting
Amoxicillin	Drops 100 mg per 1 ml; 30 ml OP, bottle	\$7.25	\$4.00	Ospamox (Sandoz)	Amoxil Paediatric Drops (GSK)
Amoxicillin	Inj 250 mg; 10 injections, vial	\$12.64	\$12.42	Ibiamox (Douglas)	Ibiamox (Douglas)*
Amoxicillin	Inj 500 mg; 10 injections, vial	\$14.46	\$14.24	Ibiamox (Douglas)	Ibiamox (Douglas)*
Amoxicillin	Inj 1 g; 10 injections, vial	\$22.00	\$21.62	Ibiamox (Douglas)	Ibiamox (Douglas)*
Aqueous Cream	Crm; 500 g, pot	\$2.37	\$2.28	AFT (AFT)	Multichem (Multichem)
Ciprofloxacin	Tab 250 mg; 30 tablets, blister	\$5.46	\$3.35	Rex Medical (Rex Medical)	Cipflox (Pacific)
Ciprofloxacin	Tab 500 mg; 30 tablets, blister	\$8.90	\$4.90	Rex Medical (Rex Medical)	Cipflox (Pacific)
Ciprofloxacin	Tab 750 mg; 30 tablets, blister	\$20.68	\$7.54	Rex Medical (Rex Medical)	Cipflox (Pacific)
Octreotide	Inj 50 mcg per ml, 1 ml; 5 injections, vial	\$43.50	\$25.65	Hospira (Hospira)	Sandostatin (Novartis)
Octreotide	Inj 100 mcg per ml, 1 ml; 5 injections, vial	\$81.00	\$48.50	Hospira (Hospira)	Sandostatin (Novartis)
Octreotide	Inj 500 mcg per ml, 1 ml; 5 injections, vial	\$399.00	\$175.00	Hospira (Hospira)	Sandostatin (Novartis)

\*In a pack size of 5 injections

### Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

3. Tenders awarded to listed pharmaceuticals where only the current brand is listed – price changes for hospital tender winning brands of the pharmaceuticals will occur in Section H of the Pharmaceutical Schedule on **1 November 2008**; DV Limits and DV Pharmaceuticals will apply from **1 January 2009**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Hospital Supply Brand (Supplier)	Pack Price	DV Limit	DV Pharmaceuticals Brand Name (Supplier)
Amoxicillin*	Inj 250 mg; 10 injections, vial	Ibiamox (Douglas)	\$12.42	1%	(B)
Amoxicillin*	Inj 500 mg; 10 injections, vial	Ibiamox (Douglas)	\$14.24	1%	(B)
Amoxicillin*	Inj 1 g; 10 injections, vial	Ibiamox (Douglas)	\$21.62	1%	(B)
Bupivacaine Hydrochloride with Fentanyl	Inj 0.125% with 2 mcg fentanyl per ml, 15 ml; 10 injections, syringe	Biomed (Biomed)	\$61.50	1%	(B)
Bupivacaine Hydrochloride with Fentanyl	Inj 0.125% with 2 mcg fentanyl per ml, 20 ml; 10 injections, syringe	Biomed (Biomed)	\$78.00	1%	(B)
Bupivacaine Hydrochloride with Fentanyl	Inf 0.125% with 2 mcg fentanyl per ml, 100 ml; 10 infusions, bag	Biomed (Biomed)	\$200.00	1%	(B)
Bupivacaine Hydrochloride with Fentanyl	Inf 0.125% with 2 mcg fentanyl per ml, 200 ml; 10 infusions, bag	Biomed (Biomed)	\$200.00	1%	(B)
Morphine Sulphate	Inj 1 mg per ml, 10 ml; 10 injections, syringe	Biomed (Biomed)	\$34.50	1%	(B)
Morphine Sulphate	Inj 1 mg per ml, 30 ml; 10 injections, syringe	Biomed (Biomed)	\$75.00	1%	(B)
Morphine Sulphate	Inj 1 mg per ml, 50 ml; 10 injections, syringe	Biomed (Biomed)	\$59.50	1%	(B)
Morphine Sulphate	Inj 2 mg per ml, 30 ml; 10 injections, syringe	Biomed (Biomed)	\$95.00	1%	(B)

\*Currently in a pack size of 5 injections.

4. Tenders awarded to listed pharmaceuticals where an alternative brand is already listed – price changes for hospital tender winning brands of the pharmaceutical will occur in Section H of the Pharmaceutical Schedule on **1 November 2008**; DV Limits and DV pharmaceuticals will apply from **1 January 2009**; De-listing of other brands in Section H will occur on **1 January 2009**.

Chemical Name	Presentation; Pack size and type	Hospital Supply Brand (Supplier)	Pack Price	DV Limit	DV Pharmaceuticals Brand Name (Supplier)
Ciprofloxacin	Tab 250 mg; 30 tablets, blister	Rex (Rex Medical)	\$3.35	1%	Cipflox (Pacific) Ciproxin (Bayer)
Ciprofloxacin	Tab 500 mg; 30 tablets, blister	Rex (Rex Medical)	\$4.90	1%	Cipflox (Pacific) Ciproxin (Bayer)
Ciprofloxacin	Tab 750 mg; 30 tablets, blister	Rex (Rex Medical)	\$7.54	1%	Cipflox (Pacific) Ciproxin (Bayer)
Octreotide	Inj 50 mcg per ml, 1 ml; 5 injections, vial	Hospira (Hospira)	\$25.65	1%	Sandostatin (Novartis)
Octreotide	Inj 100 mcg per ml, 1 ml; 5 injections, vial	Hospira (Hospira)	\$48.50	1%	Sandostatin (Novartis)
Octreotide	Inj 500 mcg per ml, 1 ml; 5 injections, vial	Hospira (Hospira)	\$175.00	1%	Sandostatin (Novartis)

5. Tenders awarded to pharmaceuticals where no brand is listed - listing of the hospital tender winning brand of the pharmaceutical will occur in Section H of the Pharmaceutical Schedule on **1 November 2008** and DV Limits and DV Pharmaceuticals will apply from **1 January 2009**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Hospital Supply Brand (Supplier)	Pack Price	DV Limit	DV Pharmaceuticals Brand Name (Supplier)
Amoxicillin	Drops 100 mg per 1 ml; 30 ml, bottle	Ospamox (Novartis)	\$4.00	1%	Amoxil Paediatric Drops (GSK)
Promethazine Hydrochloride	Tab 10 mg; 50 tablets, blister	Allersoothe (AFT)	\$2.72	1%	Phenergan (Sanofi-Aventis)
Promethazine Hydrochloride	Tab 25 mg; 50 tablets, blister	Allersoothe (AFT)	\$4.44	1%	Phenergan (Sanofi-Aventis)
Prednisone*	Tab 20 mg; 500 tablets, bottle	Apo-Prednisone (Apotex)	\$29.03	1%	Douglas (Douglas) Origen (GSK)
Zopiclone	Tab 7.5 mg; 500 tablets, bottle	Apo-Zopiclone (Apotex)	\$21.02	1%	Imovane (Sanofi-Aventis)

\*DV Limits and DV Pharmaceuticals for prednisone 20 mg tablets will apply from 1 December 2008, to be consistent with the other strengths of prednisone.

#### Products where no tender is to be awarded for Sole Subsidised Supply or Hospital Supply Status

The PHARMAC Board (or Chief Executive under delegated authority) resolved not to award tenders for Sole Subsidised Supply or Hospital Supply Status for some of the products listed in the Invitation to Tender, dated 21 December 2007.

The decisions were as follows:

Chemical Name	Line Item
Etoposide Phosphate	Inj 100 mg (of etoposide base)
Triazolam	Tab 125 mcg
Triazolam	Tab 250 mcg

#### 2006/07 Tender

1. Tenders awarded to pharmaceuticals where at least one other brand is listed – subsidy changes for tender winning brand at the tender subsidy will occur on **1 November 2008**, reference pricing of non-

tender winning brand will occur on **1 January 2009** and Sole Subsidised Supply commences on **1 April 2009**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current subsidy	New tender subsidy	Sole supply brand (Supplier)	Brands affected by reference pricing and delisting
Clotrimazole	Vaginal crm 2% with applicator(s); 20 g OP, tube	\$3.99	\$2.75	Clomazol (Multichem)	Clotrimaderm 2% (AFT)

2. Tenders awarded to pharmaceuticals where no brand is listed - listing of the hospital tender winning brand of the pharmaceutical will occur in Section H of the Pharmaceutical Schedule on **1 November 2008** and DV Limits and DV Pharmaceuticals will apply from **1 January 2009**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Hospital Supply Brand (Supplier)	Pack Price	DV Limit	DV Pharmaceuticals Brand Name (Supplier)
Clotrimazole	Vaginal crm 2% with applicator(s); 20 g OP, tube	Clomazol (Multichem)	\$2.75	1%	Canesten (Bayer) Clotrimaderm 2% (AFT)

For the remaining products on the Invitation to Tender dated 21 December 2007 and the Invitation to tender dated 15 December 2006 where no announcement has been made, either a decision is still pending, or is provisional and subject to the product gaining market approval and having sufficient stock. We will keep you informed regarding any changes for the remaining tender products as further decisions are made.

Yours sincerely



Yvonne Chen  
Tender Analyst